Drugs / ASP7962
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02136316 | May 2014 → Nov 2015 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 1 | NCT01981928 | Nov 2013 → May 2014 | — | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02611466 | Feb 2016 → Aug 2017 | chronic pain syndrome, osteoarthritis, knee | Astellas Pharma Europe B.V. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP7962 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01981928 ↗ |
| Action | Inhibit | “To investigate the TrkA inhibitor, ASP7962, for treatment of painful knee osteoarthritis.” PMID 31356878 ↗ Jul 2019 |
| Modality | Small molecule | — CHEMBL6068538 ↗ |
| Route | Oral | “Oral” NCT01981928 ↗ |